Amyotrophic lateral sclerosis and organ donation: Is there risk of disease transmission?

Annals of Neurology

Volumn 72, Issue 6, 2012, Pages 832-836

  Holmes, Brandon B ^a   Diamond, Marc I ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; PREALBUMIN; PRION PROTEIN; SOD1 PROTEIN; SYNUCLEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE TRANSMISSION; FAMILIAL AMYLOID POLYNEUROPATHY; FOLLOW UP; GENE SILENCING; HUMAN; IATROGENIC CREUTZFELDT JAKOB DISEASE; LEWY BODY; LIVER TRANSPLANTATION; ORGAN DONOR; PARKINSON DISEASE; PATHOGENESIS; PATIENT SELECTION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEPLETION; PROTEIN FOLDING; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RNA INTERFERENCE; TDP 43 PROTEINOPATHY; TEMPLATED CONFORMATIONAL CHANGE; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; COMMUNICABLE DISEASES; HUMANS; LONGITUDINAL STUDIES; RISK; TISSUE AND ORGAN PROCUREMENT;

EID: 84871982839     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23684     Document Type: Review

References (58)

1. Toossi S, Lomen-Hoerth C, Josephson SA, et al. Organ donation after cardiac death in amyotrophic lateral sclerosis. Ann Neurol 2012; 71: 154-156.
2. Baker HF, Ridley RM, Duchen LW, et al. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol 1994; 8: 25-39.
3. Ridley RM, Baker HF, Windle CP, Cummings RM,. Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 2006; 113: 1243-1251. (Pubitemid 44291018)
4. Prusiner SB,. Some speculations about prions, amyloid, and Alzheimer's disease. N Engl J Med 1984; 310: 661-663. (Pubitemid 14194391)
5. Prusiner SB,. Shattuck lecture: Neurodegenerative diseases and prions. N Engl J Med 2001; 344: 1516-1526. (Pubitemid 32429212)
6. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 1781-1784. (Pubitemid 44454153)
7. Eisele YS, Obermuller U, Heilbronner G, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010; 330: 980-982.
8. Eisele YS, Bolmont T, Heikenwalder M, et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A 2009; 106: 12926-12931.
9. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503. (Pubitemid 351655211)
10. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506. (Pubitemid 351655212)
11. Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010; 285: 9262-9272.
12. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010-13015.
13. Hansen C, Angot E, Bergström AL, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-725.
14. Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012; 33: 2225-2228.
15. Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012; 209: 975-986.
16. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11: 909-913.
17. Frost B, Ollesch J, Wille H, Diamond MI,. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem 2009; 284: 3546-3551.
18. Frost B, Jacks RL, Diamond MI,. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009; 284: 12845-12852.
19. Kfoury N, Holmes BB, Jiang H, et al. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 2012; 287: 19440-19451.
20. Braak H, Braak E,. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
21. Braak H, Braak E,. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-278; discussion 278-284.
22. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
23. Seeley WW, Crawford RK, Zhou J, et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009; 62: 42-52.
24. Zhou J, Gennatas ED, Kramer JH, et al. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 2012; 73: 1216-1227.
25. Raj A, Kuceyeski A, Weiner M,. A network diffusion model of disease progression in dementia. Neuron 2012; 73: 1204-1215.
26. Ravits J, Paul P, Jorg C,. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007; 68: 1571-1575. (Pubitemid 46717980)
27. Korner S, Kollewe K, Fahlbusch M, et al. Onset and spreading patterns of upper and lower motor neuron symptoms in amyotrophic lateral sclerosis. Muscle Nerve 2011; 43: 636-642.
28. Fujimura-Kiyono C, Kimura F, Ishida S, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 1244-1249.
29. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351: 602-611. (Pubitemid 44708852)
30. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130-133. (Pubitemid 44547757)
31. Furukawa Y, Kaneko K, Watanabe S, et al. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem 2011; 286: 18664-18672.
32. Pesiridis GS, Tripathy K, Tanik S, et al. A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport. J Biol Chem 2011; 286: 18845-18855.
33. Münch C, O'Brien J, Bertolotti A,. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S A 2011; 108: 3548-3553.
34. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46: 857-868. (Pubitemid 40805347)
35. Boutajangout A, Quartermain D, Sigurdsson EM,. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010; 30: 16559-16566.
36. Chai X, Wu S, Murray TK, et al. Passive immunization with anti-tau antibodies in two transgenic models: reduction of tau pathology and delay of disease progression. J Biol Chem 2011; 286: 34457-34467.
37. Urushitani M, Ezzi SA, Julien JP,. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2007; 104: 2495-2500. (Pubitemid 46391424)
38. Gros-Louis F, Soucy G, Lariviere R, Julien JP,. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010; 113: 1188-1199.
39. Duffy P, Wolf J, Collins G, et al. Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease. N Engl J Med 1974; 290: 692-693.
40. Hamaguchi T, Noguchi-Shinohara M, Nozaki I, et al. The risk of iatrogenic Creutzfeldt-Jakob disease through medical and surgical procedures. Neuropathology 2009; 29: 625-631.
41. Brown P, Brandel JP, Preece M, Sato T,. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006; 67: 389-393. (Pubitemid 44214958)
42. Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000; 55: 1075-1081.
43. The National Creutzfeld-Jakob Disease Surveillance Unit. Variant Creutzfeldt-Jakob disease current data. 2012. [Cited 23 June 2012.] Available from URL: http://www.cjd.ed.ac.uk/vcjdworld.htm.
44. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG,. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006; 91: 221-230. (Pubitemid 44337279)
45. Andrade C,. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427.
46. Llado L, Baliellas C, Casasnovas C, et al. Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2010; 16: 1386-1392.
47. Adams D, Lacroix C, Antonini T, et al. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. Amyloid 2011; 18 (suppl 1): 169-172.
48. Sulmasy DP,. Donation after cardiac death in amyotrophic lateral sclerosis: stepping forward into uncertain waters. Ann Neurol 2012; 71: 151-153.
49. Wang J, Xu G, Borchelt DR,. High molecular weight complexes of mutant superoxide dismutase 1: age-dependent and tissue-specific accumulation. Neurobiol Dis 2002; 9: 139-148. (Pubitemid 34261210)
50. Marucci G, Morandi L, Bartolomei I, et al. Amyotrophic lateral sclerosis with mutation of the Cu/Zn superoxide dismutase gene (SOD1) in a patient with Down syndrome. Neuromuscul Disord 2007; 17: 673-676. (Pubitemid 47362682)
51. Jonsson PA, Bergemalm D, Andersen PM, et al. Inclusions of amyotrophic lateral sclerosis-linked superoxide dismutase in ventral horns, liver, and kidney. Ann Neurol 2008; 63: 671-675.
52. Guareschi S, Cova E, Cereda C, et al. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A 2012; 109: 5074-5079.
53. Papadeas ST, Kraig SE, O'Banion C, et al. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc Natl Acad Sci U S A 2011; 108: 17803-17808.
54. Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 2011; 29: 824-828.
55. Polymenidou M, Cleveland DW,. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011; 147: 498-508.
56. Couthouis J, Hart MP, Shorter J, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A 2011; 108: 20881-20890.
57. Andersen PM, Al-Chalabi A,. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011; 7: 603-615.
58. Morris HR, Waite AJ, Williams NM, et al. Recent advances in the genetics of the ALS-FTLD complex. Curr Neurol Neurosci Rep 2012; 12: 243-250.